User:Mr. Ibrahem/Tafasitamab

Tafasitamab, sold under the brand name Monjuvi, is a medication used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when autologous stem cell transplant is not an option. It is used together with lenalidomide. It is given by gradual injection into a vein.

Common side effects include low white blood cells, tiredness, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Other serious side effects may include infusion related reactions, bone marrow suppression, and infections. Use during pregnancy may harm the baby. It is a monoclonal antibody which attaches to CD19 and stimulates the immune system to kill the cell that expresses this.

Tafasitamab was approved for medical use in the United States in 2020 and Europe in 2021. In the United States it costs about 6,400 USD per dose for a 70 kg person as of 2021. It is made by recombinant DNA technology.